Health rationing in Europe: can cancer get a fair hearing?

Anna Wagstaff

Faced with escalating drug prices and rising patient expectations, Europe’s governments are anxious to ensure value for money from their overstretched health budgets. But how can one measure the value of a few extra precious months of life, and could requirements to show strong evidence of value for money in the short term hinder the development of effective therapies over the longer term?

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.